Upadacitinib (Rinvoq) - A New JAK Inhibitor for Rheumatoid Arthritis
Upadacitinib (Rinvoq) - A New JAK Inhibitor for Rheumatoid Arthritis
November 18, 2019 (Issue: 1585)
The FDA has approved upadacitinib (Rinvoq –
Abbvie), an oral Janus kinase (JAK) inhibitor, for
treatment of adults with moderately to severely
active rheumatoid arthritis (RA) who have had
an inadequate response to or cannot...more
- Tofacitinib (Xeljanz) for rheumatoid arthritis. Med Lett Drugs Ther 2013; 55:1.
- Baricitinib (Olumiant) for rheumatoid arthritis. Med Lett Drugs Ther 2018; 60:120.
- Drugs for rheumatoid arthritis. Med Lett Drugs Ther 2018; 60:123.
- IB McInnes et al. Comparison of baricitinib, upadacitinib, and tofacitinib mediated regulation of cytokine signaling in human leukocyte subpopulations. Arthritis Res Ther. 2019; 21:183.
- R van Vollenhoven et al. A phase 3, randomized, controlled trial comparing upadacitinib monotherapy to MTX monotherapy in MTX-naïve patients with active rheumatoid arthritis. Presented at 2018 ACR/ARHP Annual Meeting. Abstract 891. Available at: http://bit.ly/2quHHK6. Accessed November 7, 2019.
- JS Smolen et al. Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study. Lancet 2019; 393:2303.
- GR Burmester et al. Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2018; 391:2503.
- R Fleischmann et al. Upadacitinib versus placebo or adalimumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: Results of a phase III, double-blind, randomized controlled trial. Arthritis Rheumatol 2019; 71:1788.
- MC Genovese et al. Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial. Lancet 2018; 391:2513.
- In brief: risk of pulmonary thromboembolism and death with tofacitinib (Xeljanz). Med Lett Drugs Ther 2019; 61:136.
- Inhibitors and inducers of CYP enzymes and P-glycoprotein. Med Lett Drugs Ther 2019; September 20 (epub). Available at: medicalletter.org/downloads/CYP_PGP_Tables.pdf.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this article? Gain access below.
Subscribe
Subscriptions to
The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App
- FREE online per issue CME/CE
Purchase this article:
Title: Upadacitinib (Rinvoq) - A New JAK Inhibitor for Rheumatoid Arthritis
Article code: 1585b
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
